Latest News and Press Releases
Want to stay updated on the latest news?
-
Dallas, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- In a recent survey conducted by Wondr Health, sixty percent of respondents said they would consider taking medication for weight loss. Of those who...
-
Inspired Announces Partnership with Kambi to Provide Virtual Sports Offering to the Kambi Sportsbook
NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services,...
-
CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
-
Duos Granted AI Patent Rail safety patent with supervised machine learning, proactively detects defects, identifies derailment risks for Rail Safety
-
CHICAGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”) today announced that it will release its fourth quarter and year-end 2023 results after the market close...
-
Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian...
-
CHARLOTTE, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT) today announced the successful completion of its acquisition...
-
LOS ANGELES, Feb. 07, 2024 (GLOBE NEWSWIRE) -- AutoTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global automotive...
-
Acronis, a global leader in cyber protection, today released the findings of its benchmarked cyberthreats report for the second half of 2023.
-
New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm Phase 1/2 study; sustained...